China's leading AI labs are accelerating plans to go public, led by Moonshot AI and DeepSeek, in what multiple outlets are calling the beginning of the country's biggest AI listing cycle to date. Moonshot has officially distributed a shareholder resolution seeking investor approval for a Hong Kong listing as early as six months from now, moving quickly to capitalize on the market attention generated by Kimi K3's benchmark-shaking release -- the same model at the center of separate US accusations of illegal distillation and export-control violations.
DeepSeek is pursuing a parallel but distinct path: the Hangzhou-based lab, widely regarded as China's most technically respected AI developer, is targeting Shanghai's STAR Market -- the city's Nasdaq-style tech board -- with a listing as early as the second quarter of 2027. DeepSeek raised $7.4 billion in its first-ever external funding round in June at a valuation north of $50 billion, and is reportedly now seeking fresh capital at a valuation as high as $71 billion ahead of that listing, a rapid re-rating for a lab that until recently operated with minimal external capital.
Other Chinese AI startups including GigaAI are moving in the same direction, and the shared motivation across all of them is straightforward: frontier AI research requires enormous, sustained compute spend, and public capital markets offer a faster, larger funding channel than continuing to raise private rounds indefinitely -- the same logic that's driven Western labs like OpenAI and Anthropic to weigh their own eventual public listings.
The complication specific to Moonshot is that its IPO roadshow will unfold under active, direct US government scrutiny: the White House has accused the company of illegally distilling Anthropic's Fable model to build Kimi K3, and separately of accessing export-controlled Nvidia GB300 chips through Thailand-based infrastructure to circumvent export controls. Both accusations, if substantiated or escalated into formal sanctions, could materially complicate a Hong Kong listing that depends partly on international investor confidence in Moonshot's legal standing.
For global AI and public-markets investors, this listing wave is the clearest evidence yet that competitive, frontier-adjacent AI development has genuinely globalized -- Chinese labs are no longer just technically competitive, they're now racing toward the same public-market capital-raising playbook Western labs have been debating for years. The comparison points are notable: DeepSeek's targeted $71 billion valuation would place it in the same tier as some Western frontier labs' most recent private marks, despite operating under a fundamentally different regulatory and export-control environment.
Watch for: whether Moonshot's Hong Kong listing timeline holds given the active US accusations against it, or whether international investor hesitation forces a delay; whether DeepSeek's valuation talks actually close at the reported $71 billion figure; and whether any of these listings draw explicit US regulatory objection given escalating tensions over Chinese AI IP and chip-export circumvention.